Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of pTVG-HP DNA Vaccine With or Without pTVG-AR DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer

NCT04090528 is registered in ClinicalTrials.gov with University of Wisconsin, Madison as lead sponsor.

NCT NCT04090528
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04090528 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of pTVG-HP DNA Vaccine With or Without pTVG-AR DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer
Lead sponsor
University of Wisconsin, Madison
Phase
Phase 2
Overall status
Active, not recruiting
Start date
October 21, 2019
Completion date
March 31, 2027
Enrollment
60 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

castration-resistant prostate cancer, metastatic cancer, prostate cancer